JP2016510038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510038A5 JP2016510038A5 JP2015560381A JP2015560381A JP2016510038A5 JP 2016510038 A5 JP2016510038 A5 JP 2016510038A5 JP 2015560381 A JP2015560381 A JP 2015560381A JP 2015560381 A JP2015560381 A JP 2015560381A JP 2016510038 A5 JP2016510038 A5 JP 2016510038A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- independently
- alkyl
- optionally substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 113
- 150000001875 compounds Chemical class 0.000 claims description 96
- 150000003839 salts Chemical class 0.000 claims description 94
- 125000000623 heterocyclic group Chemical group 0.000 claims description 86
- 229910052736 halogen Inorganic materials 0.000 claims description 63
- 150000002367 halogens Chemical class 0.000 claims description 63
- 239000003112 inhibitor Substances 0.000 claims description 61
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 41
- 125000001188 haloalkyl group Chemical group 0.000 claims description 37
- 125000003342 alkenyl group Chemical group 0.000 claims description 35
- 125000000304 alkynyl group Chemical group 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000002777 nucleoside Substances 0.000 claims description 16
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 16
- 208000031886 HIV Infections Diseases 0.000 claims description 14
- 208000037357 HIV infectious disease Diseases 0.000 claims description 14
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims description 12
- 239000003084 hiv integrase inhibitor Substances 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 11
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 10
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 10
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 8
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 8
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 8
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 8
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 8
- 210000000234 capsid Anatomy 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 229940122440 HIV protease inhibitor Drugs 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 7
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940124784 gp41 inhibitor Drugs 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 108010002459 HIV Integrase Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 125000005059 halophenyl group Chemical group 0.000 description 4
- -1 methoxy, dimethylamino Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005216 haloheteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018114786A JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771655P | 2013-03-01 | 2013-03-01 | |
| US61/771,655 | 2013-03-01 | ||
| US201361857636P | 2013-07-23 | 2013-07-23 | |
| US61/857,636 | 2013-07-23 | ||
| PCT/US2014/019663 WO2014134566A2 (en) | 2013-03-01 | 2014-02-28 | Therapeutic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018114786A Division JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510038A JP2016510038A (ja) | 2016-04-04 |
| JP2016510038A5 true JP2016510038A5 (enExample) | 2017-03-30 |
| JP6519486B2 JP6519486B2 (ja) | 2019-05-29 |
Family
ID=50382584
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560381A Active JP6519486B2 (ja) | 2013-03-01 | 2014-02-28 | Ｈｉｖの処置のためのアミド化合物 |
| JP2018114786A Active JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
| JP2019149366A Withdrawn JP2019214599A (ja) | 2013-03-01 | 2019-08-16 | Ｈｉｖの処置のためのアミド化合物 |
| JP2021177617A Withdrawn JP2022009742A (ja) | 2013-03-01 | 2021-10-29 | Ｈｉｖの処置のためのアミド化合物 |
| JP2023090106A Withdrawn JP2023101723A (ja) | 2013-03-01 | 2023-05-31 | Ｈｉｖの処置のためのアミド化合物 |
| JP2025039673A Pending JP2025085700A (ja) | 2013-03-01 | 2025-03-12 | Ｈｉｖの処置のためのアミド化合物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018114786A Active JP6893899B2 (ja) | 2013-03-01 | 2018-06-15 | Ｈｉｖの処置のためのアミド化合物 |
| JP2019149366A Withdrawn JP2019214599A (ja) | 2013-03-01 | 2019-08-16 | Ｈｉｖの処置のためのアミド化合物 |
| JP2021177617A Withdrawn JP2022009742A (ja) | 2013-03-01 | 2021-10-29 | Ｈｉｖの処置のためのアミド化合物 |
| JP2023090106A Withdrawn JP2023101723A (ja) | 2013-03-01 | 2023-05-31 | Ｈｉｖの処置のためのアミド化合物 |
| JP2025039673A Pending JP2025085700A (ja) | 2013-03-01 | 2025-03-12 | Ｈｉｖの処置のためのアミド化合物 |
Country Status (38)
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013006738A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| TWI706945B (zh) * | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
| WO2014144545A2 (en) * | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| US9873680B2 (en) | 2014-08-29 | 2018-01-23 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2016040084A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| RU2017138549A (ru) | 2015-04-23 | 2019-05-23 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Ингибиторы репликации вируса иммунодефицита человека |
| AR104388A1 (es) * | 2015-04-23 | 2017-07-19 | Bristol Myers Squibb Co | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| US20170040479A1 (en) | 2015-08-07 | 2017-02-09 | Solaero Technologies Corp. | Reliable interconnection of solar cells |
| US20170081324A1 (en) * | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| EP3478703A1 (en) | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| US10493070B2 (en) | 2016-06-30 | 2019-12-03 | Viiv Healthcare Uk (No. 5) Limited | Azadecalin derivatives as inhibitors of human immunodeficiency virus replication |
| EP3478661A1 (en) | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Aza-substituted inhibitors of human immunodeficiency virus replication |
| KR102180740B1 (ko) * | 2016-08-19 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| EA036921B1 (ru) * | 2017-02-10 | 2021-01-15 | Джилид Сайэнс, Инк. | Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич |
| UY37710A (es) * | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| TWI687415B (zh) * | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| PL3752495T3 (pl) | 2018-02-15 | 2024-01-15 | Gilead Sciences, Inc. | Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv |
| CA3175384A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
| US11505543B2 (en) | 2018-04-11 | 2022-11-22 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| WO2020031112A1 (en) | 2018-08-09 | 2020-02-13 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20220089598A1 (en) * | 2018-09-14 | 2022-03-24 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7433303B2 (ja) | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| PT3870577T (pt) | 2018-10-24 | 2025-04-07 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| JP7532354B2 (ja) | 2018-10-24 | 2024-08-13 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| WO2020084480A1 (en) | 2018-10-25 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20210403465A1 (en) | 2018-10-29 | 2021-12-30 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| JP2022506399A (ja) | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210395248A1 (en) | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| HUE059677T2 (hu) | 2019-03-22 | 2022-12-28 | Gilead Sciences Inc | Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása |
| US20220211704A1 (en) | 2019-04-30 | 2022-07-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| FI3986561T3 (fi) | 2019-06-19 | 2024-05-02 | Viiv Healthcare Uk No 5 Ltd | Pyrido[2,3-d]pyrimidiinijohdannaisia ihmisen immuunikatoviruksen replikaation estäjinä |
| JP2022551254A (ja) | 2019-10-01 | 2022-12-08 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
| ES2974657T3 (es) | 2019-10-01 | 2024-07-01 | Viiv Healthcare Uk No 5 Ltd | Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| JP2022551691A (ja) | 2019-10-08 | 2022-12-13 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
| EP4643882A2 (en) | 2019-11-26 | 2025-11-05 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 |
| WO2021104413A1 (zh) | 2019-11-29 | 2021-06-03 | 江苏恒瑞医药股份有限公司 | 稠合吡啶环衍生物、其制备方法及其在医药上的应用 |
| CN115135647A (zh) * | 2020-01-30 | 2022-09-30 | 先正达农作物保护股份公司 | 杀有害生物活性的稠合二环杂芳香族氨基化合物 |
| CA3170536A1 (en) * | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2021176367A1 (en) | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| KR20230002629A (ko) | 2020-04-15 | 2023-01-05 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| WO2021262990A1 (en) * | 2020-06-25 | 2021-12-30 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CA3195799A1 (en) | 2020-11-11 | 2022-05-19 | Stephen R. Martin | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
| CN118159529A (zh) * | 2021-05-28 | 2024-06-07 | 江苏恒瑞医药股份有限公司 | 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法 |
| EP4440702B1 (en) | 2021-12-03 | 2025-05-21 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| JP7736929B2 (ja) | 2021-12-03 | 2025-09-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| US12084467B2 (en) * | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024006982A1 (en) * | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AR132464A1 (es) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | Régimen de dosificación de inhibidor de la cápside |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| WO2024249573A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| TW202515516A (zh) * | 2023-06-15 | 2025-04-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 用於製備化合物之方法及中間物 |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202530226A (zh) | 2023-10-11 | 2025-08-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250249005A1 (en) | 2024-02-05 | 2025-08-07 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250367384A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367382A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240385A1 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| WO2025240391A2 (en) | 2024-05-14 | 2025-11-20 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
| US20250367381A1 (en) | 2024-05-14 | 2025-12-04 | Gilead Sciences, Inc. | Medical injections and related devices and methods |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2010493T3 (pl) * | 2006-04-12 | 2016-08-31 | Merck Sharp & Dohme | Pirydyloamidy jako antagoniści kanałów wapniowych typu t |
| RU2010120671A (ru) * | 2007-10-24 | 2011-11-27 | Мерк Шарп Энд Домэ Корп. (Us) | Гетероциклические фениламидные антагонисты кальциевых каналов т-типа |
| CA2702126A1 (en) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
| NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| US20120045761A1 (en) | 2009-02-25 | 2012-02-23 | Bigtec Private Limited | Probes and primers for detection of chikungunya |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20110035387A1 (en) * | 2009-08-10 | 2011-02-10 | Telcordia Technologies, Inc. | System and method for the controlled introduction of noise to information filtering |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PT2688403T (pt) | 2011-03-23 | 2017-07-13 | Trevena Inc | Ligandos de recetores opioides e métodos de uso e fabrico dos mesmos |
| PE20141066A1 (es) | 2011-04-21 | 2014-09-05 | Gilead Sciences Inc | Compuestos de benzotiazol |
| WO2013006738A1 (en) * | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| WO2013019653A1 (en) * | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| PH12014500842A1 (en) | 2012-04-20 | 2014-06-09 | Gilead Sciences Inc | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection |
| GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
| US9447134B2 (en) | 2012-08-17 | 2016-09-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| AU2014205315B2 (en) | 2013-01-09 | 2016-11-17 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TWI706945B (zh) * | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| US10035760B2 (en) | 2013-10-24 | 2018-07-31 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US9873680B2 (en) | 2014-08-29 | 2018-01-23 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2016040084A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| RU2017138549A (ru) | 2015-04-23 | 2019-05-23 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Ингибиторы репликации вируса иммунодефицита человека |
| AR104388A1 (es) | 2015-04-23 | 2017-07-19 | Bristol Myers Squibb Co | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| JP6620763B2 (ja) * | 2017-01-16 | 2019-12-18 | マツダ株式会社 | 電動車両 |
-
2014
- 2014-02-27 TW TW108101371A patent/TWI706945B/zh active
- 2014-02-27 TW TW103106785A patent/TWI694071B/zh active
- 2014-02-28 SG SG10201710764YA patent/SG10201710764YA/en unknown
- 2014-02-28 HK HK16114621.0A patent/HK1226078B/zh unknown
- 2014-02-28 ES ES14712844.1T patent/ES2688571T3/es active Active
- 2014-02-28 CN CN201480020587.0A patent/CN105705500B/zh active Active
- 2014-02-28 PT PT181815366T patent/PT3409667T/pt unknown
- 2014-02-28 SI SI201430847T patent/SI2961742T1/sl unknown
- 2014-02-28 BR BR112015021027-9A patent/BR112015021027B1/pt active IP Right Grant
- 2014-02-28 AU AU2014223973A patent/AU2014223973B2/en active Active
- 2014-02-28 SI SI201431878T patent/SI3409667T1/sl unknown
- 2014-02-28 HU HUE14712844A patent/HUE039521T2/hu unknown
- 2014-02-28 EA EA201591457A patent/EA035127B1/ru unknown
- 2014-02-28 PE PE2019001438A patent/PE20191461A1/es unknown
- 2014-02-28 CA CA2901502A patent/CA2901502C/en active Active
- 2014-02-28 NZ NZ728537A patent/NZ728537A/en unknown
- 2014-02-28 CU CUP2015000096A patent/CU24340B1/xx unknown
- 2014-02-28 EP EP14712844.1A patent/EP2961742B1/en active Active
- 2014-02-28 EP EP18181536.6A patent/EP3409667B1/en active Active
- 2014-02-28 WO PCT/US2014/019663 patent/WO2014134566A2/en not_active Ceased
- 2014-02-28 CA CA3007006A patent/CA3007006A1/en not_active Abandoned
- 2014-02-28 SG SG11201506929VA patent/SG11201506929VA/en unknown
- 2014-02-28 CN CN201810393664.7A patent/CN108516974A/zh active Pending
- 2014-02-28 KR KR1020157026837A patent/KR102229989B1/ko active Active
- 2014-02-28 MD MDA20150092A patent/MD20150092A2/ro not_active Application Discontinuation
- 2014-02-28 EP EP21184874.2A patent/EP3954679A3/en active Pending
- 2014-02-28 JP JP2015560381A patent/JP6519486B2/ja active Active
- 2014-02-28 NZ NZ631754A patent/NZ631754A/en unknown
- 2014-02-28 US US14/194,623 patent/US20140303164A1/en not_active Abandoned
- 2014-02-28 PL PL14712844T patent/PL2961742T3/pl unknown
- 2014-02-28 CR CR20190504A patent/CR20190504A/es unknown
- 2014-02-28 RS RS20181186A patent/RS57718B1/sr unknown
- 2014-02-28 PL PL18181536T patent/PL3409667T3/pl unknown
- 2014-02-28 MY MYPI2015002119A patent/MY195364A/en unknown
- 2014-02-28 US US14/771,779 patent/US9951043B2/en active Active
- 2014-02-28 MX MX2015011478A patent/MX375170B/es active IP Right Grant
- 2014-02-28 AP AP2015008717A patent/AP2015008717A0/xx unknown
- 2014-02-28 NZ NZ742681A patent/NZ742681A/en not_active IP Right Cessation
- 2014-02-28 PT PT14712844T patent/PT2961742T/pt unknown
- 2014-02-28 PE PE2015001811A patent/PE20151749A1/es unknown
- 2014-02-28 DK DK14712844.1T patent/DK2961742T3/en active
- 2014-02-28 ES ES18181536T patent/ES2887578T3/es active Active
- 2014-02-28 HR HRP20181679TT patent/HRP20181679T1/hr unknown
- 2014-02-28 UA UAA201508564A patent/UA120346C2/uk unknown
- 2014-02-28 LT LTEP14712844.1T patent/LT2961742T/lt unknown
- 2014-02-28 SM SM20180522T patent/SMT201800522T1/it unknown
- 2014-03-05 UY UY0001035362A patent/UY35362A/es not_active Application Discontinuation
-
2015
- 2015-08-12 IL IL240519A patent/IL240519B/en active IP Right Grant
- 2015-08-21 ZA ZA2015/06098A patent/ZA201506098B/en unknown
- 2015-08-26 PH PH12015501881A patent/PH12015501881A1/en unknown
- 2015-08-31 CL CL2015002445A patent/CL2015002445A1/es unknown
- 2015-09-01 CR CR20150454A patent/CR20150454A/es unknown
-
2016
- 2016-11-22 AU AU2016262671A patent/AU2016262671B2/en active Active
- 2016-12-22 HK HK18114165.0A patent/HK1260892A1/zh unknown
-
2018
- 2018-03-02 US US15/910,083 patent/US20180273508A1/en not_active Abandoned
- 2018-06-15 JP JP2018114786A patent/JP6893899B2/ja active Active
- 2018-09-12 CY CY181100946T patent/CY1121047T1/el unknown
- 2018-10-15 AU AU2018247348A patent/AU2018247348A1/en not_active Abandoned
-
2019
- 2019-08-16 JP JP2019149366A patent/JP2019214599A/ja not_active Withdrawn
-
2020
- 2020-05-26 US US16/882,804 patent/US20210009555A1/en active Pending
-
2021
- 2021-10-29 JP JP2021177617A patent/JP2022009742A/ja not_active Withdrawn
-
2023
- 2023-05-31 JP JP2023090106A patent/JP2023101723A/ja not_active Withdrawn
-
2025
- 2025-03-12 JP JP2025039673A patent/JP2025085700A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510038A5 (enExample) | ||
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2016527217A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP2017522273A5 (enExample) | ||
| JP2015511638A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2016506959A5 (enExample) | ||
| AR072249A1 (es) | Inhibidores de amida hidrolasa de acido graso. usos. metodos. | |
| JP2014511892A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2011521938A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2017525699A5 (enExample) | ||
| JP2008517923A5 (enExample) | ||
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| JP2016512507A5 (enExample) | ||
| JP2015535247A5 (enExample) |